Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Claris Lifesciences is currently trading at Rs. 215.55, up by 13.65 points or 6.76% from its previous closing of Rs. 201.90 on the BSE.
The scrip opened at Rs. 227.00 and has touched a high and low of Rs. 234.90 and Rs. 210.20 respectively. So far 843666 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 267.00 on 02-Jun-2015 and a 52 week low of Rs. 126.10 on 12-Feb-2016.
Last one week high and low of the scrip stood at Rs. 234.90 and Rs. 159.80 respectively. The current market cap of the company is Rs. 1189.58 crore.
The promoters holding in the company stood at 60.99% while Institutions and Non-Institutions held 21.37% and 17.64% respectively.
Claris Lifesciences, one of India's largest sterile Injectables company, has received the Establishment Inspection Report (EIR) for its manufacturing facility located near Ahmedabad, wherein the US FDA has concluded that the inspection stands closed and the facility was found to be acceptable. The US FDA had conducted audit at the company’s manufacturing facility in May, 2015, the company had taken appropriate steps to address the observations it had received from these audits.
Having received the EIR from the US FDA potentially clears the path for the company to receive product approvals (ANDA) for the USA. The company presently has 13 ANDAs approved in the USA which account for about $200 million of market size and it has an additional 26 ANDAs, with an addressable market size of around $1.5 billion under approval. The company expects 5-7 ANDA approvals in the near future and these ANDAs approvals could increase the addressable market size of the company's products in the USA by around $240 million.
Claris is also one of the few injectables companies in India to have its own front end in the US, the company markets its products through its wholly owned subsidiary Claris Lifesciences Inc. The company has 13 ANDAs approved in its name across 8 molecules. The company has a under registration pipeline of 24 ANDAs across 21 molecules having an estimated addressable market size of $2.2 billion.
| Company Name | CMP |
|---|---|
| Adani Enterprises | 3384.65 |
| Redington | 206.15 |
| Amrapali Industries | 14.42 |
| Rashi Peripheral | 333.00 |
| Compuage Infocom | 4.15 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
